Zoetis Inc. (ZTS)

Market Cap	72.26B
Revenue (ttm)	9.26B
Net Income (ttm)	2.49B
Shares Out	447.79M
EPS (ttm)	5.47
PE Ratio	29.50
Forward PE	26.57
Dividend	$2.00 (1.24%)
Ex-Dividend Date	Apr 21, 2025

Volume	1,273,413
Open	163.47
Previous Close	163.17
Day's Range	160.25 - 164.35
52-Week Range	144.80 - 200.33
Beta	0.94
Analysts	Strong Buy
Price Target	217.56 (+34.82%)
Earnings Date	May 1, 2025

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 13,800
• Stock Exchange: NYSE
• Ticker Symbol: ZTS
• Website: https://www.zoetis.com

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Analyst Forecast

According to 9 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $217.56, which is an increase of 34.82% from the latest price.

Price Target

$217.56

(34.82% upside)

Analyst Consensus: Strong Buy